Navelbine Oral (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine Oral, is a Vinca alkaloid presented as an oral tablet for oral use. It is employed in the treatment of certain advanced solid tumours, notably non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navelbine Oral as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is used as a chemotherapeutic agent in malignancies that respond to microtubule inhibition. - Non‑small cell lung cancer: improves disease control and overall survival when combined with standard regimens. - Metastatic breast cancer: provides tumour shrinkage and palliation in patients who have progressed after prior therapies.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Nausea and vomiting: gastrointestinal upset common after dosing. - Constipation: decreased bowel motility. - Alopecia: hair thinning or loss. - Fatigue: generalised tiredness.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection: can be life‑threatening. - Pulmonary toxicity: dyspnoea, interstitial pneumonitis. - Peripheral neuropathy: tingling or numbness in extremities. - Hypersensitivity reactions: rash, pruritus, anaphylaxis. - Hypotension: sudden drop in blood pressure. - Cardiac arrhythmias: rare but possible QT prolongation.

Before initiating therapy, clinicians should assess baseline health status and monitor for known risks. - Blood count monitoring: perform complete blood counts regularly to detect myelosuppression. - Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically. - Pulmonary evaluation: screen for pre‑existing lung disease before treatment. - Pregnancy avoidance: drug is contraindicated in pregnancy; use effective contraception. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Vinorelbine may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine exposure. - Concurrent myelosuppressive agents: amplify risk of severe bone‑marrow suppression. - Live vaccines: immunosuppression may reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels. - Anticoagulants (e.g., warfarin): monitor INR for potential bleeding. - QT‑prolonging drugs (e.g., macrolide antibiotics): watch for cardiac rhythm changes.